Work

Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.3604

Authors: R. Kurzrock, W. Akerley, D. Hong, C. Ng, T. Warren, K. Zavitz, C. McCage, M. Laughlin, L. Camacho

Institutions: The University of Texas MD Anderson Cancer Center, Huntsman Cancer Institute

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2966045481

Cites:

Cited by: 5

Related to: 10